| HOME >> BIOLOGY >> TECHNOLOGY |
CHARLESTOWN, S.C., Feb. 1 /PRNewswire-USNewswire/ -- First-String Research, Inc. (FSR), a spin-off biotechnology company from the Medical University of South Carolina (MUSC), has begun the human clinical trial process for its unique, wound-healing peptide gel. Already past the preliminary approval stages, the "First in Man" trial will take place in Switzerland thanks to the assertive attention of Swiss investors. Initial preclinical studies have suggested the gel's efficacy and safety in regenerating new tissue, instead of scar tissue, in order to heal wounds better and faster than any product currently on the market.
In the clinical trial, four different doses of the gel will be administered to study participants with deep wounds. Those wounds will be examined periodically, and positive results from the study could put FSR's wound-healing gel one step closer to FDA approval. Currently, there are no mechanistically-based products approved by the FDA that can reduce or eliminate scarring and promote wound regeneration. "We have received an enormous amount of positive feedback from the investment community at large, including industry experts who were astonished at what we were able to achieve with such little funding," said Gautam Ghatnekar, Ph.D., FSR President and co-inventor of the gel peptide. "This product truly marks a paradigm shift from healing with a disfiguring scar to encouraging normal tissue regeneration."
It was in the lab of Robert Gourdie, Ph.D., MUSC professor of cell biology and Clemson professor of bioengineering, that the original peptide was created. Now on the FSR board of directors, Gourdie remains excited about the potential of technology he co-invented with Ghatnekar. "This peptide has tremendous potential in all body situations that involve healing because it regulates and modifies intercellular communication at the site of the wound," he said.
Since the company began a few years ago, FSR has been pleasantly
'/>"/>
| SOURCE MEDICAL UNIVERSITY OF SOUTH CAROLINA Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
2. The Jordan Company, L.P. Has Teamed with the Management of Haas TCM Inc. to Form Haas TCM Group Inc.
3. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
4. Burrill & Company Announces Promotions
5. Thermage, Inc. to Present at the 10th Annual Needham & Company Growth Conference
6. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
7. National Stem Cell Holding, Inc. Posts Company and Financial Information on the OTCIQ and Has Retained New CFO and Counsel to File Registration Statement With SEC
8. BioMed Realty Trust Appoints Executive Officer of the Irvine Company to Its Board
9. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
10. Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
11. International Substance Detection Firm IDenta To Release New Lead Test Kit - Rash Of Toy Incidents Leads Company To Enter New Marketplace
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |